1428 related articles for article (PubMed ID: 11441936)
21. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
22. A systematic overview of chemotherapy effects in urothelial bladder cancer.
Nilsson S; Ragnhammar P; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):371-90. PubMed ID: 11441942
[TBL] [Abstract][Full Text] [Related]
23. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.
Cole BF; Gelber RD; Gelber S; Coates AS; Goldhirsch A
Lancet; 2001 Jul; 358(9278):277-86. PubMed ID: 11498214
[TBL] [Abstract][Full Text] [Related]
24. Present state and future prospects: a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer.
Mamounas EP
Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S20-30. PubMed ID: 11970741
[TBL] [Abstract][Full Text] [Related]
25. A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma.
Kimby E; Brandt L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):198-212. PubMed ID: 11441932
[TBL] [Abstract][Full Text] [Related]
26. [Metastatic breast cancer: what are the objectives?].
Salvini P; Ripa C; Ginanni V
Tumori; 2000; 86(5 Suppl 1):S22-8. PubMed ID: 11195289
[TBL] [Abstract][Full Text] [Related]
27. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.
Kimby E; Brandt L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):224-30. PubMed ID: 11441934
[TBL] [Abstract][Full Text] [Related]
28. WITHDRAWN: Tamoxifen for early breast cancer.
Clarke MJ
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000486. PubMed ID: 18843611
[TBL] [Abstract][Full Text] [Related]
29. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
30. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
31. Treatment of breast cancer in countries with limited resources.
Carlson RW; Anderson BO; Chopra R; Eniu AE; Jakesz R; Love RR; Masetti R; Schwartsmann G;
Breast J; 2003; 9 Suppl 2():S67-74. PubMed ID: 12713499
[TBL] [Abstract][Full Text] [Related]
32. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
[TBL] [Abstract][Full Text] [Related]
33. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
Gelber RD; Cole BF; Goldhirsch A; Rose C; Fisher B; Osborne CK; Boccardo F; Gray R; Gordon NH; Bengtsson NO; Sevelda P
Lancet; 1996 Apr; 347(9008):1066-71. PubMed ID: 8602056
[TBL] [Abstract][Full Text] [Related]
35. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
36. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
37. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
Eifel P; Axelson JA; Costa J; Crowley J; Curran WJ; Deshler A; Fulton S; Hendricks CB; Kemeny M; Kornblith AB; Louis TA; Markman M; Mayer R; Roter D
J Natl Cancer Inst; 2001 Jul; 93(13):979-89. PubMed ID: 11438563
[TBL] [Abstract][Full Text] [Related]
38. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel
J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
[TBL] [Abstract][Full Text] [Related]
39. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
Tormey DC; Gray R; Falkson HC
J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
